Fulcrum Therapeutics (FULC) Equity Ratio (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Equity Ratio data on file, last reported at 0.96 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.96, up 2.07% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.96 (up 2.07% YoY), and the FY2025 annual result was 0.95, up 2.21% from the prior year.
• Equity Ratio improved to 0.96 in Q1 2026 per FULC's latest filing, from 0.95 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.96 in Q1 2026 and troughed at 0.82 in Q2 2022.
• A 5-year average of 0.91 and a median of 0.92 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio slipped 2.51% in 2022, then increased 11.38% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.88 in 2022, then advanced by 4.0% to 0.91 in 2023, then rose by 2.14% to 0.93 in 2024, then gained by 2.21% to 0.95 in 2025, then grew by 0.88% to 0.96 in 2026.
• Business Quant data shows FULC's Equity Ratio at 0.96 in Q1 2026, 0.95 in Q4 2025, and 0.92 in Q3 2025.